



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)


[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Mirdametininib

## Chemical Properties

CAS No. :	391210-10-9
Formula:	C <sub>16</sub> H <sub>14</sub> F <sub>3</sub> IN <sub>2</sub> O <sub>4</sub>
Molecular Weight:	482.19
Appearance:	no data available
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year



## Biological Description

Description	Mirdametininib (PD325901) is an MEK inhibitor (IC <sub>50</sub> =0.33 nM) with selective, non-ATP-competitive, and oral activity. Mirdametininib exhibits antitumor activity by inhibiting p-ERK1/2 expression and inducing apoptosis.
Targets(IC <sub>50</sub> )	Apoptosis,MEK,Autophagy
In vitro	<p><b>METHODS:</b> Eleven human melanoma cell lines were treated with Mirdametininib (0.1-1000 nM) for 72 h, and cell counts were determined using the trypan blue exclusion test.</p> <p><b>RESULTS:</b> Mirdametininib (IC<sub>50</sub>=20-50 nM) effectively inhibited the growth of human melanoma cell lines with BRAF mutations (M14/A375P/A375M/A375SM/ME10538/ME4686/JR8) or without BRAF mutations (ME4405/ME13923). ME8959 both have wild-type BRAF and are slightly more resistant to Mirdametininib-mediated growth inhibition (IC<sub>50</sub>≥100 nM). [1]</p> <p><b>METHODS:</b> Papillary thyroid carcinoma (PTC) cell lines K2 and TPC-1 were treated with Mirdametininib (0.1-1000 nmol/L) for 1-96 h. Target protein expression levels were detected by Western Blot.</p> <p><b>RESULTS:</b> Mirdametininib effectively inhibited the phosphorylation of ERK1/2 in various PTC cell lines. [2]</p>
In vivo	<p><b>METHODS:</b> To assay antitumor activity in vivo, Mirdametininib (20-25 mg/kg, 80 mmol/L citric buffer (pH 7)) was administered by gavage to Athymic Ncr-nu/nu mice harboring PTC tumors K2 or TPC-1 five times per week for three weeks.</p> <p><b>RESULTS:</b> Mirdametininib completely inhibited tumor growth in mice inoculated with PTC cells K2 harboring BRAF mutations and significantly reduced tumor growth in mice inoculated with PTC cells TPC-1 harboring RET/PTC1 rearrangements. [2]</p> <p><b>METHODS:</b> To assay anti-tumor activity in vivo, Mirdametininib (1.6-25 mg/kg, 0.5% hydroxypropylmethylcellulose + 0.2% Tween 80 in water) was administered orally to mice bearing mouse colorectal cancer tumor CT26 once daily for fourteen days.</p> <p><b>RESULTS:</b> Mirdametininib significantly inhibited pERK levels in tumors. [3]</p>
Kinase Assay	Incorporation of <sup>32</sup> P into myelin basic protein (MBP) is assayed in the presence of a glutathione S-transferase fusion protein containing p44MAP kinase (GST-MAPK) and a glutathione S-transferase protein containing p45MEK (GST-MEK). The assay solution contained 20 mM HEPES, pH 7.4, 10 mM MgCl <sub>2</sub> , 1 mM MnCl <sub>2</sub> , 1 mM EGTA, 50 mM [γ- <sup>32</sup> P] ATP, 10 mg GST-MEK, 0.5 mg GST-MAPK and 40 mg MBP in a final volume of 100 mL. Reactions are stopped after 20 minutes by addition of trichloroacetic acid and filtered through a GF/C filter mat. <sup>32</sup> P retained on the filter mat is determined using a 1205

	Betaplate [1].
Cell Research	A cell death detection enzyme-linked immunosorbent assay was used per the manufacturer's instructions. Briefly, $4 \times 10^4$ cells were plated in 24-well plates in triplicate the day before treatment. PTC cells were treated with 0.1 $\mu\text{mol/L}$ PD0325901 for 96 hours. Cells treated with 1 $\mu\text{mol/L}$ staurosporine served as positive controls for apoptosis. At the end of treatment, cells were lysed using the lysis buffer provided in the kit for 30 minutes at room temperature and then centrifuged in 24-well plates. Lysates (20 $\mu\text{L}$ of supernatant) were transferred to streptavidin-coated wells and incubated for 2 hours at room temperature with two antibodies (biotin-labeled anti-histone antibody and peroxidase-conjugated anti-DNA antibody). After the wells were washed three times, the samples were incubated with peroxidase substrate (ABTS) and the amount of colored product was determined spectrophotometrically at 405 nm. The background was measured at 490 nm [2].
Animal Research	Athymic Ncr-nu/nu mice were obtained from the National Cancer Institute at ages 6 to 8 weeks and housed for at least 1 week after arrival. Mice (10-14 per group) were anesthetized s.c. with a cocktail (100 $\mu\text{L}/10$ g body weight of 10 mg/mL ketamine and 1 mg/mL xylazine). K2 and TPC-1 cells stably infected with a retrovirus expressing luciferase ( $5 \times 10^5$ cells in 5 $\mu\text{L}$ RPMI1640 medium) were inoculated into the thyroid gland, and the mice were monitored weekly for tumor growth by Xenogen (IVIS 200 imaging system) using Living Image 3.0 software. One week after inoculation, PD0325901 was dissolved in 80 mmol/L citric buffer (pH 7) by sonication and given to mice daily by oral gavage (20-25 mg/kg) for 3 weeks (5 consecutive days/week). Mice were sacrificed only due to tumor burden or loss of 20% of body weight. Tumor sizes were measured with calipers and tumor volume (V) was calculated by the formula ( $V = \text{length} \times \text{width} \times \text{depth}$ ). Control mice were given 80 mmol/L citric buffer (pH 7) alone. All in vivo experiments were done at least twice [2].

### Solubility Information

Solubility	H <sub>2</sub> O: Insoluble, DMSO: 50 mg/mL (103.69 mM), ( $< 1$ mg/ml refers to the product slightly soluble or insoluble)
------------	---

### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.0739 mL	10.3694 mL	20.7387 mL
5 mM	0.4148 mL	2.0739 mL	4.1477 mL
10 mM	0.2074 mL	1.0369 mL	2.0739 mL
50 mM	0.0415 mL	0.2074 mL	0.4148 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

### Reference

Ciuffreda L, et al. Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. *Neoplasia*. 2009 Aug;11(8):720-31.  
Guo Z, Guo L, Qin J, et al. A

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481